poisar

Stocks · News reference

HCW Biologics Requests For Type B Meeting With FDA To Discuss Development, Regulatory Path For Its HCW11-018b Candidate To Treat Solid Tumors

BenzingaJul 23, 2026, 12:02 PMBenzinga Newsdesk

HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 23, 2026, 12:02 PM
Checked
Jul 23, 2026, 12:02 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading